New Delhi: With more mutations than Covid-19 Coronavirus is likely that in the near future, there might be a need for India to adopt a dose of booster with a second generation covid vaccine, said Dr.
Randeep Guleria, Director, AIIMS.
In an interview with the news agency, Dr.
Guleria said, “It seems that we might need a booster dose because with the passage of time, immunity tends to be reduced.
We want to have a booster dose that will also protect against the variant that arises.” Director AIIMS said, “Second Generation Vaccine said It would be better in terms of the immunity they gave against the emerging variants and a better overall efficacy.
The shooting of the booster vaccine shooting has already taken place.
After the entire population vaccinated, the next step is to manage a booster dose.
“Dr.
Guleria also expects a trial of Covaxin Bharat Biotech for children, currently underway with the results that is expected to be released in September, to pave the way for vaccines for children.
He showed that Zydus Cadila also entered data for children in the vaccine data when applying for emergency use permits.
He said that in the coming weeks or in September, the children’s vaccine must be available.
“We must start school in a valuable way after vaccinating students as we have done for a population of 18-45 years,” he said.
The delay in the procurement of vaccines even though the Indian government holds talks with modern vaccine producers and Pfizer, the Head of AIIMS said, “There may be several reasons for delays.
I think two or three things to remember.
Someone is collaboration and understanding with the government at the dose.
The company must also Having an additional dose.
To give us because we know they have orders that have been ordered earlier from many countries and are required to provide vaccines to these countries.
Unless this obligation is fulfilled, they cannot release the doses for countries such as India.
” India has discussed with two companies about problems such as compensation.
Dr.
V K Paul, Member (Health), Niti Aayog, previously said India tried to resolve contracts and commitment problems with the two companies.